Waters stock
WATNYSEWaters Corporation, HealthcareISIN US9418481035
56Score 56 out of 100, Neutral
Price and trend
89 / 100
Price history
+22% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 26% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 56).
The price is 1.9% below its 52-week high. Largest decline in 20 years: 62% (January 2008 to March 2009).
Chart figures for advanced users
- SMA 50$438.27
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$372.39
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)56
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$283.32
- The lowest closing price of the last twelve months.
- Resistance$480.07
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Waters Corporation belongs to the Medical (Diagnostics & Research) industry (United States) and, with a market value of $46.24B, is number 7 of 37 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $3.17B (up 7% year on year) and earnings of $642.63M (up 0.8%).
- For fiscal 2026, analysts expect on average revenue of $6.49B (up 105%) and adjusted earnings per share of $14.68 (up 11.8%).
Show more
- MEQIRI Score 56 out of 100 (Neutral): rank 330 of 714 in Healthcare, median 53.
- The P/E is 473 because earnings over the last twelve months collapsed; on the expected earnings of the next twelve months it is 28.9 (Medical (Diagnostics & Research) median 33.7). The P/E therefore does not count in the score.
- Our model puts fair value at $264.15, with the price 78% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 297% of earnings over the last 12 months.Fundamentals 80
- High return on capitalReturn on invested capital 22.8% in fiscal 2025, Medical (Diagnostics & Research) median 6.4%.
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 80
Weaknesses
- Above fair valuePrice 78% above the fair value of $264.15.Valuation 16
Its standout strengths are technical analysis and momentum, while capital allocation and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 55 to 56.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 9 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- price near its 52-week high
- solid fundamentals
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $203.19 and expensive above $377.35 (uncertainty medium, based on the price swings of the past year).
Calculated with a cost of equity of 9.5%. At 10.5% the fair value would be $221.88, at 8.5% it would be $324.68.
Valuation metrics
From the cash-flow model alone; after a one-off collapse in earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 3 Oct 2026, revenue rose 80.7% on the twelve months before. Revenue has grown solidly since 2006, at about 5% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 58%, operating 28%, net 20%. Last 12 months: net 2%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 8 Feb 2027in 88 days
- Last reported
- 3 Nov 2026EPS reported $4.10 (expected $4.00)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $14.68+0.7%
- Revenue
- $6.49B+0.5%
- Earnings per share
- $16.53+0.2%
- Revenue
- $7.16B+0.5%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +6.7%2026 guidance raised: organic constant currency revenue growth 7% to 9%, adjusted EPS $14.45 to $14.65; adjusted EBIT margin of 28.2% as previously expected.
“With this strong momentum, we are raising our full year 2026 organic constant currency revenue growth guidance to 7% to 9%. Foreign exchange translation is now expected to be a headwind of approximately 60 basis points, resulting in 2026 organic reported revenue of $3.37 billion to $3.431 billion.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 4 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $1.44M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Kuebler Christopher ASale
6 Aug 2026, Board
- Shares
- 3,626
- Price
- $397.94
- Value
- $1.44M
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Waters
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 56
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Diagnostics & Research)
The next larger and next smaller companies by market value
- WuXi AppTec603259.SS $67.65B84
- IDEXX LaboratoriesIDXX $55.35B79
- Agilent TechnologiesA $49.89B77
- NateraNTRA $46.38B43
- IQVIA HoldingsIQV $45.24B67
- Mettler-Toledo InternationalMTD $35.04B76
- IlluminaILMN $32.2B70
- Labcorp HoldingsLH $30.23B64
ETFs that hold Waters
Held by 124 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares MSCI World Health Care Sector Advanced UCITS ETFCBUF | 0.83% | 0.18% | €837.43M |
| UBS Factor MSCI USA Prime Value Screened UCITS ETF hEUR accUBUW | 0.68% | 0.28% | €127.84M |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 0.67% | 0.15% | €3.27B |
Show 5 more
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 0.67% | 0.12% | €1.34B |
| UBS Factor MSCI USA Quality Screened UCITS ETF hEUR accUBUX | 0.67% | 0.28% | €1.14B |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 0.66% | 0.15% | €592.11M |
| Deka MSCI USA MC UCITS ETFEL41 | 0.56% | 0.30% | €51.58M |
| Xtrackers MSCI World Health Care UCITS ETF 1CXDWH | 0.48% | 0.25% | €4.18B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 15 May 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.